01 1Wavelength Pharmaceuticals
01 1CISATRACURIUM BESYLATE PROCESS B
01 1Israel
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-19
Pay. Date : 2024-01-22
DMF Number : 39123
Submission : 2024-01-29
Status : Active
Type : II
20
Wavelength Enterprises Ltd, based in Israel, is a pharmaceutical company that stands out with its certifications from EDQM.
One of their notable products is CISATRACURIUM BESYLATE PROCESS B, with a corresponding US DMF Number 39123.
Remarkably, this DMF maintains an Active status since its submission on January 29, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 19, 2024, and payment made on January 22, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II
